Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Launched by NATIONAL CANCER INSTITUTE (NCI) · May 24, 2004

Keywords

ClinConnect Summary

This clinical trial is focused on collecting blood and urine samples from patients who are receiving radiation therapy for glioblastoma multiforme, which is a type of brain tumor. The goal of the study is to understand how radiation treatment affects blood cells and specific proteins in the body. Researchers hope that this information will help in developing new tests to measure how much radiation patients are exposed to, identify which patients or tumors respond best to radiation therapy, and potentially find new ways to treat cancer. Two important proteins being studied are VEGF and MMPs, which may play a role in cancer recurrence.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of glioblastoma multiforme. They should also be able to receive radiation therapy and be in good enough health to participate. During the trial, participants will have blood and urine samples taken before, during, and after their radiation treatment. The blood will be drawn through a needle in their arm, and urine will be collected in a cup. The study is currently recruiting participants, and those who join may also be asked for additional samples during the treatment and for up to three years afterward.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Age greater than or equal to 18 years.
• • Histologically confirmed supratentorial Glioblastoma multiforme.
• • Karnofsky performance \>60.
• • Patient must be a candidate for radiotherapy.
• • Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
• EXCLUSION CRITERIA:
• • Patients with other cancers excluding non-melanomatous skin cancers or carcinoma in situ.
• • Gliadel wafer placement at the time of surgery.
• • Pregnancy because radiation has the potential for teratogenic or abortifacient effects.
• • \<TAB\>\<TAB\>